



Graeme Smith
Chief Scientific Officer, Artios Pharma Ltd.

Graeme is CSO at Artios with responsibility for the scientific strategy and drug discovery projects in the DNA Damage Response (DDR) area. Prior to Artios, Graeme held the positions of Senior Project Leader and Senior Director of Bioscience at AstraZeneca within the Oncology therapy area. In these roles Graeme led teams in the discovery and development of novel anti-cancer agents delivering novel therapies into the clinic. Graeme was Research Director at KuDOS Pharmaceuticals where he was a co-inventor of Lynparza[™] (olaparib) and the concept of synthetic lethality in a DDR defective background eg BRCA1/2 loss. Lynparza was the first PARP inhibitor to reach the market in 2014. Graeme has published and patented extensively in the field.